Abstract
Proper bone development requires the coordinated and calibrated action of various cells, hormones, enzymes and nutrients. In this paper, we present two clinical cases of metabolic bone disorders – one with excessive fibroblast growth factor-23 (FGF23) and the other, with low alkaline phosphatase. FGF23 and alkaline phosphatase are not-so-well-known players in bone health. This paper puts the spotlight on these two, and discusses their role in bone development, and how abnormal levels lead to disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
